Discovery could broaden effectiveness of emerging therapies for cancer and other diseases that are based on boosting the natural immune system response
Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to maximize the effectiveness of anti-cancer immune therapy. The researchers identified a molecular switch that controls immune suppression, opening the possibility to further improving and refining emerging immunotherapies that boost the body’s own abilities to fight diseases ranging from cancer to Alzheimer’s and Crohn’s disease.
The findings are published in the September 19 online issue of Nature.
“Immunotherapies, such as T cell checkpoint inhibitors, are showing great promise in early treatments and trials, but they are not universally effective,” said Judith A. Varner, PhD, professor in the Departments of Pathology and Medicine at UC San Diego School of Medicine. “We have identified a new method to boost the effectiveness of current immune therapy. Our findings also improve our understanding of key mechanisms that control cancer immune suppression and could lead to the development of more effective immunotherapies.”
When confronted by pathogens, injury or disease, the initial response of the body’s immune system comes in the form of macrophages, a type of white blood cell that express pro-inflammatory proteins called cytokines that, in turn, activate T cells, another immune cell, to attack the health threat. The macrophages then switch gears to express other cytokines that dampen T cell activation, stimulating tissue repair.
In chronic inflammatory diseases such as Alzheimer’s and Crohn’s, however, macrophages associated with the malignancy continue to produce pro-inflammatory cytokines and other substances that kill or transform normal cells. In cancer, highly abundant microphages express anti-inflammatory cytokines that induce immune suppression, effectively stopping the healing process.
In the Nature paper, Varner and colleagues pinpoint a key, suspected player: an enzyme in macrophages called PI-3 kinase gamma (PI3Ky). In mouse studies, they found that macrophage PI3Ky signaling promotes immune suppression by inhibiting activation of anti-tumor T cells. Blocking PI3Ky activated the immune response and significantly suppressed growth of implanted tumors in animal models. It also boosted sensitivity of some tumors to existing anti-cancer drugs and synergized with existing immune therapy to eradicate tumors. Varner and her colleagues at the Moores Cancer Center also identified a molecular signature of immune suppression and response in mice and cancer patients that may be used to track the effectiveness of immunotherapy.
“Recently developed cancer immunotherapeutics, including T cell checkpoint inhibitors and vaccines, have shown encouraging results in stimulating the body’s own adaptive immune response,” said co-author Ezra Cohen, MD, who heads the cancer immunotherapy program at Moores Cancer Center. “But they are effective only on a subset of patients, probably because they do not alter the profoundly immunosuppressive microenvironment created by tumor-associated macrophages. Our work offers a strategy to maximize patient responses to immune therapy and to eradicate tumors. ”
The Nature paper builds upon other work by Varner and colleagues. In a paper first published online in May in Cancer Discovery, Varner’s team reported that blocking PI3Ky in tumor-associated macrophages stimulated the immune response and inhibited tumor cell invasion, metastasis and fibrotic scarring caused by pancreatic ductal adenocarcinoma (PDAC) in animal models.
In humans, PDAC is the most common malignancy of the pancreas It’s aggressive and difficult to treat. Though only the 12th most common type of cancer in the United States, pancreatic cancer is the fourth most common cause of cancer-related death.
“PDAC has one of the worst 5-year survival rates of all solid tumors, so new treatment strategies are urgently needed,” said Megan M. Kaneda, PhD, an assistant project scientist in Varner’s lab and collaborator on all of the papers.
In a December 2015 paper published online in Cancer Discovery, Varner and colleagues described animal studies that revealed how disrupting cross-talk between B cells (another type of immune cell) and tumor-associated macrophages inhibited PDAC growth and improved responsiveness to standard-of-care chemotherapy.
Specifically, that research team, which included scientists in San Francisco, Oregon and Switzerland, reported that inhibiting Bruton tyrosine kinase, an enzyme that plays a crucial role in B cell and macrophage functions, restored T cell-dependent anti-tumor immune response. In other words, it reactivated the natural, adaptive immune response in tested mice.
The Latest on: Immune Suppression
via Google News
The Latest on: Immune Suppression
- Exposure to Oil and Hypoxia Results in Alterations of Immune Transcriptional Patterns in Developing Sheepshead Minnows (Cyprinodon variegatus)on February 3, 2020 at 2:18 am
In the second transition, oil exposure significantly altered many immune pathways (43), and while hypoxia altered few pathways, it did induce a unique signature of generally suppressing immune ...
- Cancer Cells Exploit Double Bind in Immune Escape Acton January 31, 2020 at 3:45 pm
They observed the early steps that cancer cells take when the follow the programmed death-1 (PD-1) pathway to suppress T-cell stimulation and accomplish immune escape. These steps involve ...
- Why a growing biopharm firm is trading one local college for anotheron January 31, 2020 at 11:11 am
A Philadelphia-area biopharmaceutical company developing new technology to treat cancer and immune-related disorders has moved from one college campus to another. Navrogen Inc., which was founded last ...
- Researchers identify possible new combination treatment for advanced melanomaon January 31, 2020 at 9:43 am
to promote the development and expansion of the infused immune cells. But interleukin 2 can also activate cells to suppress the immune system, and because it is highly toxic, it can have serious ...
- Navrogen Opens R&D Operations At Cheyney Universityon January 31, 2020 at 6:42 am
/PRNewswire/ -- Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announced the ...
- Immuno-oncology combination for melanoma using Nektar drug boosts cell therapy in miceon January 31, 2020 at 5:35 am
Problem is, interleukin-2 can simultaneously activate cells that suppress the immune system, and it can cause dangerous side effects. So the UCLA team wanted to see whether a different immunotherapy ...
- Cardiac Cell Therapy: Dead or Alive?on January 31, 2020 at 5:22 am
What the new work doesn’t address is the potential of induced pluripotent stem cells (IPSCs) as possible means of regenerating damaged heart tissue, although given Molkentin’s work, Kass says he would ...
- Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellson January 30, 2020 at 2:38 am
The mechanisms of primary resistance are only beginning to be understood, and include tumor-cell-intrinsic oncogenic alterations, parallel immune suppressive pathways, adaptive resistance mechanisms, ...
- T. gondii parasite employs a sophisticated manipulation to suppress host's immune responseon January 24, 2020 at 10:50 am
Toxoplasma's "success," scientists believe, owes in part to its ability to evade the immune response of its host, whichever warm-blooded vertebrate it has infected. Now a new study suggests the ...
via Bing News